A new study published in the Jan. 4, 2024, print issue of Cell sheds light on the tissue-specific actions of JAK1, revealing a potential need for a more nuanced therapeutic approach in treating allergy and inflammatory disorders.

Conducted by researchers at the Icahn School of Medicine at Mount Sinai, the study, led by dermatologist Brian Kim, identified that intrinsic JAK1 signaling in sensory neurons had an immunoprotective effect in the lung, despite its known role in promoting skin inflammation and being a major therapeutic target for atopic dermatitis-related itching.

The findings suggest that a personalized approach may be necessary to expand JAK inhibitor use to a wider range of allergy and inflammatory disorders, indicating the need for more precise treatment strategies.

This new insight could have significant implications for the development of targeted therapies for conditions such as atopic dermatitis and other inflammatory disorders, potentially leading to more effective and tailored treatment options for patients.